Lupin, an Indian pharmaceutical company, has announced the launch of Darunavir Tablets, available in 600mg and 800mg variants in the US.

These tablets serve as a generic equivalent to Janssen Products’ Prezista Tablets (darunavir).

Darunavir, the active ingredient in both the 600mg and 800mg tablets, is a highly potent protease inhibitor used in the treatment of human immunodeficiency virus type 1 (HIV-1) infection. By inhibiting the action of the viral protease enzyme, Darunavir helps prevent the replication of the virus, thus controlling the progression of the disease.

With estimated annual sales of approximately $308 million in the US, according to IQVIA MAT data from March 2023, Lupin aims to tap into the lucrative market of antiretroviral medication.

  Darunavir Tablets, HIV-1, Lupin, Prezista Tablets, USA